scholarly journals Sustained long-term hematologic recovery despite a marked quantitative defect in the stem cell compartment of patients with aplastic anemia after immunosuppressive therapy

2000 ◽  
Vol 65 (2) ◽  
pp. 123-131 ◽  
Author(s):  
J.P. Maciejewski ◽  
S. Kim ◽  
E. Sloand ◽  
C. Selleri ◽  
N.S. Young
Blood ◽  
1996 ◽  
Vol 88 (6) ◽  
pp. 1983-1991 ◽  
Author(s):  
JP Maciejewski ◽  
C Selleri ◽  
T Sato ◽  
S Anderson ◽  
NS Young

We examined the stem cell compartment of patients with acquired aplastic anemia (AA) using the long-term culture-initiating cell assay (LTC-IC), in parallel with measurements of CD34+ cells and mature hematopoietic progenitors. Secondary colonies from cells surviving 5 weeks of long-term bone marrow culture (LTBMC) were determined for the peripheral blood (PB) of 68 AA patients and 13 normal controls and for BM of 49 AA patients and 14 controls; because of low cell numbers, formal limiting dilution analysis could only be performed in 10 patients. The relationship of cell input in LTBMC and the output of secondary colonies was linear, allowing quantification of LTC-IC number from bulk cultures. Secondary colony formation was markedly abnormal in severe AA. In contrast to 7.8 colony-forming cells (CFC)/10(5) mononuclear cells in normal BM and 0.14 CFC/10(5) normal PB mononuclear cells, patients with severe disease showed 0.024 CFC/10(5) in BM and 0.0068 CFC/10(5) in PB. Under limiting dilution conditions, patients' cells also showed markedly lower colony-forming ability. In contrast to 4.3 +/- 1 colonies/normal LTC-IC, we obtained only 1.27 +/- 0.09 and 2.0 +/- 0.35 colonies from BM of acute and recovered cases, respectively. These values were used to extrapolate LTC-IC numbers from secondary colony formation in suspension cultures. In PB, calculated LTC-IC were decreased 7.4-fold in new and relapsed severe AA and 2.8- fold in recovered AA. In BM, LTC-IC were decreased 10-fold in new and relapsed AA and sixfold in recovered cases. Compared with measurements obtained on presentation, LTC-IC were lower in post-treatment samples from patients who had failed to recover after intensive immunosuppression and relatively higher in cases at relapse. In recovered patients, LTC-IC number increased but remained below the normal range in 20 of 25. In patients studied serially for 3 to 12 months after treatment, LTC-IC numbers remained stable but low. LTC-IC number correlated with concurrently determined CD34+ cell number and primary hematopoietic colony formation. These results indicate that stem cell numbers, as quantitated by the LTC-IC assay, are markedly diminished in number in all severe AA. Additionally, the function of the stem cell or the stem cell compartment in AA is also abnormal, as inferred from the low clonogenic potential in secondary colony assays. Early hematologic improvement in some patients occurs without increasing numbers of LTC-IC, and a minority of recovered cases show apparent repopulation of the LTC-IC compartment years after treatment.


1985 ◽  
Vol 459 (1 Hematopoietic) ◽  
pp. 221-231 ◽  
Author(s):  
K.-H. V. WANGENHEIM ◽  
H.P, PETERSON, ◽  
G. E. HÜBNER ◽  
L. E. FEINENDEGEN

Blood ◽  
2008 ◽  
Vol 112 (11) ◽  
pp. 443-443
Author(s):  
Marcin Wlodarski ◽  
Sanjay Mohan ◽  
Lukasz Gondek ◽  
Jungwon Huh ◽  
Michael Clemente ◽  
...  

Abstract Aplastic anemia (AA) is characterized by pancytopenia due to contraction/destruction of stem cell compartment. Most investigators consider the presence of clonal cytogenetic abnormalities as incompatible with the AA diagnosis. Despite excellent response rates to immunosuppression (IS) in the majority of AA patients, clonal malignant evolution to myelodysplasia (MDS) can occur in 10–15% in 10 years. Among such cases monosomy 7 (mono7) is the most commonly reported cytogenetic abnormality. Routine metaphase cytogenetics (MC) depends upon high numbers of dividing cells with inducible mitosis and is therefore often noninformative in AA. The inability to early detect AA patients at risk for clonal evolution constitutes a significant clinical problem. We hypothesized that high resolution SNP-array technology (SNPA) that allows for the analysis of interphase genomes will improve detection of chromosomal abnormalities in MDS evolving from AA. In addition to MC, we applied Affymetrix chips to study whole genomes of AA patients (N=100; 69 and 67 were investigated using 50K/250K and 6.0 arrays, respectively; 25 patients were studied at multiple time points prior and post IS). Data was analyzed using CNAG v3.0 and Genotyping Console v2.0 and unbalanced lesions were detected, including regions of genomic gain, loss and copy number neutral loss of heterozygozity. Clonal malignant evolution was observed in 13 patients resulting in a conversion rate of 13%. We focused on longitudinal analysis of these patients. Abnormal endpoint MC was detected in a total of 69% of transformed patients (mono7 in 8/13, t(10;18)(q11.2;q21) in 1/13 and trisomy 12 in 1/13 patients, respectively). Remarkably in 5/13 (38%) of evolving AA patients, numerical aberrations were detected earlier by SNPA than MC. Mono7 (N=4) and trisomy 12 (N=1) were detected by SNPA in aspirates that showed normal or noninformative MC, while in subsequent analysis bone marrow exams concurred with the early diagnosis by SNPA. In 3 patients, MC and SNPA results were concordant and in 1 patient SNPA failed to early identify mono7,. Acquired uniparental disomy of various chromosomes was detected in a total of 4 patients and the analysis of nonmyeloid CD3+ cells revealed somatic nature of these lesions: 7q31.31–31.33(4.9mb), 17q11.2-qter(56mb), 6p12.1-pter(56mb) and 3q12.2-qter(97mb). Interestingly, 2 patients with UPD had normal concurrent MC and the clonal lesions were detected before clinical diagnosis of MDS was established. It is likely that depletion of stem cell compartment might favor detection of pseudoclonality manifested as non-pathogenic random chromosomal lesions. In our cohort, in 2 AA patients with normal MC, SNPA analysis prior to IS therapy revealed clonal UPD as confirmed by comparison of myeloid lineage with germ line configuration in CD3+ cells. These lesions disappeared post IS in both patients and nearly 2 years later a newly recruited pathogenic clone with mono7 was detected as a sole abnormality by SNPA and MC. These patients are very illustrative as they may point towards genomic instability as well as depletion of available stem cell pool resulting in frequent recruitment of defective SC. Our study demonstrates that SNPA is a powerful tool to early identify AA patients harboring clonal defects consistent with the diagnosis of MDS, and thus it potentially might have strong clinical implications.


2017 ◽  
Vol 215 (2) ◽  
pp. 627-644 ◽  
Author(s):  
Jung-Mi Lee ◽  
Vinothini Govindarajah ◽  
Bryan Goddard ◽  
Ashwini Hinge ◽  
David E. Muench ◽  
...  

Obesity is a chronic organismal stress that disrupts multiple systemic and tissue-specific functions. In this study, we describe the impact of obesity on the activity of the hematopoietic stem cell (HSC) compartment. We show that obesity alters the composition of the HSC compartment and its activity in response to hematopoietic stress. The impact of obesity on HSC function is progressively acquired but persists after weight loss or transplantation into a normal environment. Mechanistically, we establish that the oxidative stress induced by obesity dysregulates the expression of the transcription factor Gfi1 and that increased Gfi1 expression is required for the abnormal HSC function induced by obesity. These results demonstrate that obesity produces durable changes in HSC function and phenotype and that elevation of Gfi1 expression in response to the oxidative environment is a key driver of the altered HSC properties observed in obesity. Altogether, these data provide phenotypic and mechanistic insight into durable hematopoietic dysregulations resulting from obesity.


Blood ◽  
2011 ◽  
Vol 118 (14) ◽  
pp. 3853-3861 ◽  
Author(s):  
Yi Zhang ◽  
Sandra Stehling-Sun ◽  
Kimberly Lezon-Geyda ◽  
Subhash C. Juneja ◽  
Lucie Coillard ◽  
...  

Abstract The Mds1 and Evi1 complex locus (Mecom) gives rise to several alternative transcripts implicated in leukemogenesis. However, the contribution that Mecom-derived gene products make to normal hematopoiesis remains largely unexplored. To investigate the role of the upstream transcription start site of Mecom in adult hematopoiesis, we created a mouse model with a lacZ knock-in at this site, termed MEm1, which eliminates Mds1-Evi1 (ME), the longer, PR-domain–containing isoform produced by the gene (also known as PRDM3). β-galactosidase–marking studies revealed that, within hematopoietic cells, ME is exclusively expressed in the stem cell compartment. ME deficiency leads to a reduction in the number of HSCs and a complete loss of long-term repopulation capacity, whereas the stem cell compartment is shifted from quiescence to active cycling. Genetic exploration of the relative roles of endogenous ME and EVI1 isoforms revealed that ME preferentially rescues long-term HSC defects. RNA-seq analysis in Lin−Sca-1+c-Kit+ cells (LSKs) of MEm1 documents near complete silencing of Cdkn1c, encoding negative cell-cycle regulator p57-Kip2. Reintroduction of ME into MEm1 LSKs leads to normalization of both p57-Kip2 expression and growth control. Our results clearly demonstrate a critical role of PR-domain–containing ME in linking p57-kip2 regulation to long-term HSC function.


Sign in / Sign up

Export Citation Format

Share Document